[Federal Register Volume 87, Number 237 (Monday, December 12, 2022)]
[Notices]
[Pages 76051-76052]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-26888]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30Day-23-1279]


Agency Forms Undergoing Paperwork Reduction Act Review

    In accordance with the Paperwork Reduction Act of 1995, the Centers 
for Disease Control and Prevention (CDC) has submitted the information 
collection request titled ``WISEWOMAN National Program Evaluation'' to 
the Office of Management and Budget (OMB) for review and approval. CDC 
previously published a ``Proposed Data Collection Submitted for Public 
Comment and Recommendations'' notice on August 22, 2022 to obtain 
comments from the public and affected agencies. CDC received two 
comments related to the previous notice. This notice serves to allow an 
additional 30 days for public and affected agency comments.
    CDC will accept all comments for this proposed information 
collection project. The Office of Management and Budget is particularly 
interested in comments that:
    (a) Evaluate whether the proposed collection of information is 
necessary for the proper performance of the functions of the agency, 
including whether the information will have practical utility;
    (b) Evaluate the accuracy of the agencies estimate of the burden of 
the proposed collection of information, including the validity of the 
methodology and assumptions used;
    (c) Enhance the quality, utility, and clarity of the information to 
be collected;
    (d) Minimize the burden of the collection of information on those 
who are to respond, including, through the use of appropriate 
automated, electronic, mechanical, or other technological collection 
techniques or other forms of information technology, e.g., permitting 
electronic submission of responses; and
    (e) Assess information collection costs.
    To request additional information on the proposed project or to 
obtain a copy of the information collection plan and instruments, call 
(404) 639-7570. Comments and recommendations for the proposed 
information collection should be sent within 30 days of publication of 
this notice to www.reginfo.gov/public/do/PRAMain. Find this particular 
information collection by selecting ``Currently under 30-day Review--
Open for Public Comments'' or by using the search function. Direct 
written comments and/or suggestions regarding the items contained in 
this notice to the Attention: CDC Desk Officer, Office of Management 
and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202) 
395-5806. Provide written comments within 30 days of notice 
publication.

Proposed Project

    WISEWOMAN National Program Evaluation (OMB Control No. 0920-1279, 
Exp. 12/31/2022)--Extension--National Center for Chronic Disease 
Prevention and Health Promotion (NCCDPHP), Centers for Disease Control 
and Prevention (CDC).

Background and Brief Description

    The CDC has supported the WISEWOMAN (Well-Integrated Screening and 
Evaluation for Women Across the Nation) program since 1995. The 
WISEWOMAN program is designed to serve low-income women ages 40-64 who 
have elevated risk factors for cardiovascular disease (CVD) and have no 
health insurance, or are underinsured for medical and preventive care 
services. Through the WISEWOMAN program, women have access to screening 
services for selected CVD risk factors such as elevated blood 
cholesterol, hypertension, and abnormal blood glucose levels; referrals 
to heathy behavior support programs; and referrals to medical care. 
WISEWOMAN participants must be co-enrolled in the CDC-sponsored 
National Breast and Cervical Cancer Early Detection Program (NBCCEDP).
    The WISEWOMAN program is administered through cooperative 
agreements with state, territorial, or tribal health departments. Each 
WISEWOMAN recipient submits to CDC an annual progress report that 
describes program objectives and activities, and semi-annual data 
reports (known as minimum data elements, or MDEs) on the screening, 
assessment, and healthy behavior support services offered to women who 
participate in the program. Participant-level MDEs are de-identified 
prior to transmission to CDC.
    In 2018, CDC released the fifth funding opportunity announcement 
(FOA) for the WISEWOMAN program (DP18-1816), which resulted in five-
year cooperative agreements with 24 state, territorial, and tribal 
health departments, including six new and 18 continuing awardees from 
the previous NOFO. Key program elements were retained (e.g., provision 
of screening services, promotion of healthy lifestyle behaviors, and 
linkage to healthy behavior support services and community based 
resources), but a number of changes were incorporated into the program 
at that time. The current FOA reflects increased emphasis on three 
strategies to reduce CVD risk and support hypertension control and 
management, including: (1) tracking and monitoring clinical measures; 
(2) implementing team-based care; and (3) linking community resources 
and clinical services to support care coordination, self-management, 
and lifestyle change.
    CDC seeks to conduct a multi-component evaluation to assess the 
effectiveness of the program on individual, organizational, and 
community-level outcomes. The in-depth assessment is designed to 
complement the routine progress and MDE information already being 
collected from WISEWOMAN program recipients. The data collection 
focuses on obtaining qualitative and quantitative information at the 
organizational and community levels about process and procedures 
implemented, and barriers, facilitators, and other contextual factors 
that affect program implementation and participant outcomes. Data 
collection activities include a Program Survey with all WISEWOMAN 
awardee programs, administered in the second and fourth program years, 
and a one-time site visit to each recipient spread across the three-
year data collection effort. During site visits, semi-structured 
interviews will be conducted with WISEWOMAN staff members and staff at 
partner organizations, such as clinical providers and community-based 
resource providers, who are positioned to provide a variety of 
perspectives on program implementation.
    CDC requests OMB approval for a one-year extension of this data 
collection, and requests approval for an estimated 84 annual burden 
hours. Participation is voluntary and there are no costs to respondents 
other than their time.

Estimated Annualized Burden Hours

[[Page 76052]]



----------------------------------------------------------------------------------------------------------------
                                                                                     Number of    Average burden
          Type of respondents                   Form name            Number of     responses per   per response
                                                                    respondents     respondent      (in hours)
----------------------------------------------------------------------------------------------------------------
WISEWOMAN Recipient Administrators....  Program survey..........              16               1               1
                                        Site Visit Discussion                  8               1           90/60
                                         Guide.
                                        Innovation Site Visit                  2               1           45/60
                                         Discussion Guide.
Recipient partners....................  Site Visit Discussion                 16               1               1
                                         Guide.
                                        Innovation Site Visit                  2               1           45/60
                                         Discussion Guide.
Healthy behavior support staff........  Site Visit Discussion                 16               1               1
                                         Guide.
                                        Innovation Site Visit                  2               1           45/60
                                         Discussion Guide.
Clinical providers....................  Site Visit Discussion                 16               1               1
                                         Guide.
                                        Innovation Site Visit                  2               1           45/60
                                         Discussion Guide.
----------------------------------------------------------------------------------------------------------------


Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Scientific 
Integrity, Office of Science, Centers for Disease Control and 
Prevention.
[FR Doc. 2022-26888 Filed 12-9-22; 8:45 am]
BILLING CODE 4163-18-P